⌘K
Loading ticker…
As of 2026-08-24, Atossa Therapeutics, Inc. Common Stock (ATOS) has a 3-month relative strength percentile of 7 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 31. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 7.6%, relative volume 0.95×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
ATOS is held by 2 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $1M notional.
Held by 2 ETFs · $2M across latest filings · largest weight 0.00% (VXF).
Top 2 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $1M | new |
| VXFVanguard Extended Market ETF | 0.00% | $455K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ATOS Jan avg: 8.38% median: -3.60% win: 25% σ: 28.97% n: 4 2022-04-12 → 2026-07-31 | ATOS Feb avg: -12.49% median: -8.32% win: 25% σ: 25.82% n: 4 2022-04-12 → 2026-07-31 | ATOS Mar avg: 22.20% median: 8.35% win: 50% σ: 43.30% n: 4 2022-04-12 → 2026-07-31 | ATOS Apr avg: -0.76% median: -11.40% win: 40% σ: 20.30% n: 5 2022-04-12 → 2026-07-31 | ATOS May avg: 2.36% median: -3.73% win: 20% σ: 24.68% n: 5 2022-04-12 → 2026-07-31 | ATOS Jun avg: -3.43% median: 6.81% win: 60% σ: 36.90% n: 5 2022-04-12 → 2026-07-31 | ATOS Jul avg: -1.04% median: 0.48% win: 60% σ: 12.00% n: 5 2022-04-12 → 2026-07-31 | ATOS Aug avg: -9.34% median: -5.33% win: 25% σ: 13.23% n: 4 2022-04-12 → 2026-07-31 (current) | ATOS Sep avg: 2.08% median: 2.09% win: 50% σ: 11.91% n: 4 2022-04-12 → 2026-07-31 | ATOS Oct avg: 0.66% median: -3.18% win: 50% σ: 12.95% n: 4 2022-04-12 → 2026-07-31 | ATOS Nov avg: -7.86% median: -9.20% win: 25% σ: 14.53% n: 4 2022-04-12 → 2026-07-31 | ATOS Dec avg: -15.65% median: -25.75% win: 25% σ: 22.82% n: 4 2022-04-12 → 2026-07-31 |